Pivotal Bioventure Partners Investment Advis
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$279.8M
Q ending 2026-03-31
Prior quarter
$258.7M
Q ending 2025-12-31
Change
+8.2% QoQ · +126.4% YoY
Positions
13
reported holdings
Largest positions
All 13 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Vaxcyte Inc | PCVX | Shares | $79.8M | 1.4M |
| Oculis Holding Ag | Shares | $44.7M | 1.7M | |
| Evommune Inc | EVMN | Shares | $44.3M | 1.9M |
| Arcutis Biotherapeutics Inc | ARQT | Shares | $31.9M | 1.4M |
| Trevi Therapeutics Inc | TRVI | Shares | $18.5M | 1.6M |
| Immunome Inc | IMNM | Shares | $16.0M | 733K |
| Maplight Therapeutics Inc | MPLT | Shares | $12.4M | 611K |
| Zenas Biopharma Inc | ZBIO | Shares | $11.6M | 592K |
| Bioage Labs Inc | BIOA | Shares | $11.4M | 653K |
| Avalo Therapeutics Inc | AVTX | Shares | $4.4M | 296K |
| Rallybio Corp | RLYB | Shares | $2.7M | 301K |
| Recursion Pharmaceuticals In | RXRX | Shares | $1.8M | 596K |
| Bolt Biotherapeutics Inc | BOLT | Shares | $172K | 43K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.